Inmode

INMD · NASDAQ

$13.97−$0.08 (−0.57%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $14.05

INMD analyst rating

HoldConsensus of 4 analysts over the last 12 months. 25% rate it a buy.

Strong buy0
Buy1
Hold3
Underperform0
Sell0

12-month price target · 5 analysts

Average $16.49 (+18.0% upside)

Low: $15.15
Now: $13.97
High: $17.85

Upgrades and downgrades

The latest rating actions, newest first

INMD analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Barclays	May 7, 2026	Maintains	Overweight	$21.00 → $19.00	57%
Baird	May 7, 2026	Maintains	Neutral	$17.00 → $14.00	55%
Canaccord Genuity	Dec 17, 2025	Maintains	Hold	$16.00 → $15.00	43%
UBS	Nov 6, 2025	Maintains	Neutral	$16.25 → $16.00	50%

The case for and against

Updated Jan 19, 2026

Bull case

InMode Ltd demonstrated significant growth in 2Q25, selling 971 systems, contributing to a global installed base of approximately 28,855 units, with 12,347 units located in the U.S., marking a 3.4% increase from the previous quarter. The company also achieved an operating margin of 27.5%, surpassing prior estimates and reflecting a year-over-year improvement of 40 basis points. Moreover, the U.S. domestic sales reached $49.7 million, indicating a robust 9% growth compared to a decline in the previous quarter, underpinning the positive trajectory of the aesthetics market driven by rising consumer and physician interest.

Bear case

InMode Ltd is expected to experience a contraction in its margins, which, while currently among the highest in the med tech sector, signals potential challenges ahead. Furthermore, the company's earnings per share (EPS) growth is forecasted to lag behind revenue growth, indicating a weakening profitability outlook. Additionally, the bear case scenario predicts a revenue compound annual growth rate (CAGR) of less than 5% over the next few years due to slower growth from existing products and limited adoption of new offerings.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.